Cell-based Influenza Vaccination Offer Measurable Benefits

CSL Seqirus today announced new data from several studies that reinforce the benefits of cell-based influenza vaccines among people.

On October 16, 2024, Seqirus stated results from multiple real-world evidence studies over different seasons showed improved relative vaccine effectiveness of cell-based vaccines compared with egg-based vaccines in preventing outpatient test-confirmed influenza across various age groups.

“The results from these studies, collected and analyzed over several recent influenza seasons, have shown that cell-based influenza vaccines are effective in preventing both test-confirmed and clinically diagnosed influenza,” stated Mendel Haag, Senior Director, Center of Outcomes Research & Epidemiology at CSL Seqirus, in a press release.

As of October 2024, the U.S. CDC recommends that people speak with a healthcare provider, such as a pharmacist, about which of nine different flu shots is best for their needs.

The CDC says flu vaccines for the 2024-2025 season will be trivalent. Most will be thimerosal-free or thimerosal-reduced vaccine, and about 21% will be egg-free.

As of September 21, 2024, over 92 million flu shots had been distributed to clinics and pharmacies in the U.S., targeting the 2024-2025 flu season.